These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 33216980)
1. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Fouzia NA; Sharma V; Ganesan S; Palani HK; Balasundaram N; David S; Kulkarni UP; Korula A; Devasia AJ; Nair SC; Janet NB; Abraham A; Mani T; Lakshmanan J; Balasubramanian P; George B; Mathews V Br J Haematol; 2021 Jan; 192(2):292-299. PubMed ID: 33216980 [TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
3. A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Kulkarni U; Ganesan S; Alex AA; Palani H; David S; Balasundaram N; Venkatraman A; Thenmozhi M; Jeyaseelan L; Korula A; Devasia A; Abraham A; Janet NB; Balasubramanian P; George B; Mathews V Cancer Med; 2020 Apr; 9(8):2603-2610. PubMed ID: 32059085 [TBL] [Abstract][Full Text] [Related]
4. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521 [TBL] [Abstract][Full Text] [Related]
5. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy. Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159 [TBL] [Abstract][Full Text] [Related]
6. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361 [TBL] [Abstract][Full Text] [Related]
7. Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series. Fang YG; Huang SL; Chen NN J Integr Med; 2024 Sep; 22(5):614-620. PubMed ID: 39183097 [TBL] [Abstract][Full Text] [Related]
8. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912 [TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
10. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. Gore SD; Gojo I; Sekeres MA; Morris L; Devetten M; Jamieson K; Redner RL; Arceci R; Owoeye I; Dauses T; Schachter-Tokarz E; Gallagher RE J Clin Oncol; 2010 Feb; 28(6):1047-53. PubMed ID: 20085935 [TBL] [Abstract][Full Text] [Related]
11. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675 [TBL] [Abstract][Full Text] [Related]
12. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393 [TBL] [Abstract][Full Text] [Related]
13. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593 [TBL] [Abstract][Full Text] [Related]
14. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003 [TBL] [Abstract][Full Text] [Related]
15. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Aznab M; Rezaei M Hematol Oncol; 2017 Mar; 35(1):113-117. PubMed ID: 26310595 [TBL] [Abstract][Full Text] [Related]
16. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602 [TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661 [TBL] [Abstract][Full Text] [Related]
18. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF; Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769 [TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103 [TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]